81 results on '"Afdhal, N."'
Search Results
2. PGI3 LEAN AND OBESE PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) / NON-ALCOHOLIC FATTY LIVER DISEASE (NALFD); COMPARISONS OF POPULATIONS AND DISEASE PROGRESSION
3. PIN2 REAL-WORLD EFFECTIVENESS OF HEPATITIS C VIRUS (HCV) TREATMENT WITH DIRECT-ACTING ANTIVIRALS (DAA) IN POPULATIONS WITH FATTY LIVER/NON-ALCOHOLIC STEATOHEPATITIS (FL/NASH), DECOMPENSATED CIRRHOSIS (DCC), HEPATOCELLULAR CARCINOMA (HCC), AND/OR POST LIVER TRANSPLANT (PTX)
4. PIN7 REAL-WORLD EFFECTIVENESS OF DIRECT-ACTING ANTIVIRALS (DAA) IN YOUNG ADULT (18-25) AND ELDERLY (80+) POPULATIONS WITH HEPATITIS C (HCV)
5. PIN8 HEPATITIS B TREATMENT PATTERNS IN US CLINICAL CARE FOLLOWING TENOFOVIR ALAFENAMIDE (TAF) APPROVAL
6. PIN9 CLINICAL PRACTICE EXPERIENCE WITH TENOFOVIR ALAFENAMIDE (TAF) FOR TREATMENT OF HEPATITIS B IN THE US
7. PIN79 ACCESS TO HCV CURE UNDER MEDICAID PROGRAMS IN THE UNITED STATES
8. Evaluation of SOMAscan as a discovery platform to identify noninvasive protein biomarkers for diagnosis and monitoring of NASH
9. Utilization and outcomes of elbasvir/grazoprevir in genotype 1B chronic hepatitis C: updated retrospective data analyses from the Trio network
10. Accurate prediction of clinical disease progression in patients with advanced fibrosis due to NASH using a Bayesian machine learning approach
11. Whole exome sequencing identifies rare nonsense mutations enriched among patients with advanced fibrosis due to nonalcoholic steatohepatitis
12. The association of circulating microRNAs (miRs) with liver fibrosis stage and the impact of selonsertib treatment in patients with NASH
13. Effectiveness of sofosbuvir and ledipasvir/sofosbuvir based regimens in hepatitis C virus genotype 3 infection: real-world data from Georgian hepatitis C elimination program
14. Impact of HCV viral load on elbasvir/grazoprevir effectiveness in Chronic Hepatitis C: Updated retrospective data analyses from the Trio network
15. Dose response and safety of the daily, oral RIG-I agonist Inarigivir (SB 9200) in treatment naïve patients with chronic hepatitis B: results from the 25mg and 50mg cohorts in the ACHIEVE trial
16. Effects of SB9200 (Inarigivir) therapy on immune responses in patients with chronic hepatitis B
17. Prediction of fibrosis improvement in patients with advanced fibrosis due to NASH using a machine learning approach: Unravelling the placebo response
18. Effectiveness of elbasvir/grazoprevir in patients with cirrhotic genotype 1 or 4 chronic hepatitis C: updated retrospective data analyses from the Trio network
19. The conundrum of cryptogenic liver disease with advanced fibrosis: Poor clinical outcomes without treatment options
20. Identification of serum protein biomarkers for non-invasive discrimination between NASH and simple steatosis using SOMAscan
21. Effectiveness of 8 vs. 12 week ledipasvir-sofosbuvir (LDV/SOF) in black, treatment naive patients with non-cirrhotic, genotype 1 HCV and baseline viral load
22. Serum bile acids are markedly elevated in patients with compensated cirrhosis due to nonalcoholic steatohepatitis (NASH)
23. Hepatitis C care cascade in the country of Georgia after 2 years of starting national hepatitis C elimination program
24. Real world effectiveness of Ledipasvir/Sofosbuvir based regimens in hepatitis C virus genotype 1,2 and 3 infection within national hepatitis C elimination program in the country of Georgia
25. Utilization of DAA therapies ledipasvir/sofosbuvir and sofosbuvir/ velpatasvir in patients with genotype 1 HCV: real-world experience from the TRIO Network
26. Real-world effectiveness of sofosbuvir and ledipasvir/sofosbuvir based regimens in hepatitis C virus genotype 3 infection within national hepatitis C elimination program in the country of Georgia
27. Changes in fibrosis, but not the NAFLD Activity Score (NAS), are associated with disease progression in patients with nonalcoholic steatohepatitis (NASH) and advanced fibrosis
28. Elbasvir/Grazoprevir effectiveness in patients with Chronic Hepatitis C and Chronic Kidney Disease: real-world experience from the TRIO Network
29. Impact of modest weight reduction on liver histology, portal pressure, and clinical events in patients with compensated cirrhosis due to nonalcoholic steatohepatitis
30. Efficacy and safety of simtuzumab for the treatment of nonalcoholic steatohepatitis with bridging fibrosis or cirrhosis: results of two phase 2b, dose-ranging, randomized, placebo-controlled trials
31. Efficacy and safety of simtuzumab for the treatment of primary sclerosing cholangitis: results of a phase 2b, dose-ranging, randomized, placebo-controlled trial
32. Real-world treatment utilization and results in the renaissance of HCV Care: analyses of treatment for 7,550 Patients from the TRIO Network
33. Utilization of sofosbuvir/velpatasvir in genotype 2–6 HCV: real-world experience from the TRIO network
34. Impact of weight reduction on serum markers and liver histology including progression to cirrhosis in patients with nonalcoholic steatohepatitis (NASH) and bridging fibrosis
35. Real-world use of elbasvir/grazoprevir and outcomes in patients with chronic hepatitis C: retrospective data analyses from the TRIO Network
36. Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection
37. Antiviral Efficacy and Host Immune Response Induction with SB 9200, an Oral Prodrug of the Dinucleotide SB 9000, in Combination with Entecavir in the Woodchuck Model of Chronic Hepatitis B
38. SOF/VEL for 12 Weeks Results in High SVR12 Rates in Subjects with Negative Predictors of Response to Treatment: An Integrated Analysis of Efficacy from the Astral-1, Astral-2 and Astral-3 Studies
39. Genome-Wide Association Study of Clinically Significant Portal Hypertension in Patients with Nonalcoholic Steatohepatitis and Advanced Fibrosis
40. PNPLA3 Variants Confer an Increased Risk of Advanced Fibrosis Due to Non-Alcoholic Steatohepatitis
41. Ledipasvir/Sofosbuvir+/−Ribavirin in Patients Co-Infected with HCV and HIV: Real-World Heterogeneous Population from the Trio Network
42. Correlation between the Hepatic Venous Pressure Gradient and Alpha-Smooth Muscle Actin (SMA) Expression in Patients with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
43. No Effect of Proton Pump Inhibitor (PPI) Use on SVR with Ledipasvir/Sofosbuvir (LDV/SOF): Real World Data from 2034 Genotype 1 Patients in the Trio Network
44. Ledipasvir/Sofosbuvir ± Ribavirin in HCV Post-Transplant Patients: Real-World Heterogeneous Population from the Trio Network
45. HCV Eradication Results in Reduction of Hepatic Venous Pressure Gradient 48 Weeks after End of Treatment; Final Results of the Study of Sofosbuvir plus Ribavirin in Patients with Cirrhosis and Portal Hypertension
46. Resistance Analyses for Ledipasvir/Sofosbuvir Containing Regimens in Patients Infected with Chronic HCV who Have Advanced Liver Disease or are Post Liver Transplant (Solar-1 & 2 Studies)
47. SB 9200, a Novel Agonist of Innate Immunity, Shows Potent Antiviral Activity against Resistant HCV Variants
48. The Optimal Timing of Hepatitis C Therapy in Transplant Eligible Patients with Child B and C Cirrhosis: A Cost-Effectiveness Analysis
49. P0773 : The prevalence and the effect of HCV NS5A resistance associated variants in subjects with compensated cirrhosis treated with ledipasvir/sofosbuvir +/- RBV
50. P0779 : Ledipasvir/sofosbuvir with ribavirin for the treatment of fibrosing cholestatic hepatitis C after liver transplantation
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.